Remove Compounding Remove Immunization Remove Presentation
article thumbnail

STAT+: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more

STAT

So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. … A trade group representing large compounding pharmacies has sued the U.S. We trust you have your own hectic agendas. Have a grand day, everyone, and do stay in touch.

article thumbnail

Trial highlights potential next-gen biologic for lung cancer

European Pharmaceutical Review

the biologic has the potential to deliver anti-tumour responses in the majority of patients with ES-SCLC” The ongoing Phase I trial is assessing the antibody-drug conjugate both as a single treatment and as a combination therapy together with the immune checkpoint inhibitor atezolizumab.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

This high compound annual growth rate of 23.6% was powered by the advent of immune-checkpoint inhibitors, added Chalk. Checkpoint modulators, cytokines and oncolytic viruses are also considered as part of the overall immune-oncology field. Click here to watch this webinar and access the presentation.

article thumbnail

BioNTech to jointly develop novel antibody for cancers

European Pharmaceutical Review

This therefore aims to produce fewer immune-related adverse effects and a positive safety profile. “The data presented by OncoC4 on their ONC-392 monoclonal antibody indicate a differentiated safety profile and encouraging clinical activity in various types of tumors. OncoC4 will receive $200 million upfront.

article thumbnail

Company profile: NeoImmuneTech

pharmaphorum

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI.

article thumbnail

Exscientia starts trials of first AI-derived cancer immunotherapy

pharmaphorum

The adenosine pathway has emerged as an attractive target for immuno-oncology R&D because it is thought to reduce the activity of misfunctioning regulatory T-cells that inhibit the immune response against cancers. Exscientia will lead the clinical development of the A2A drug, with Evotec retaining co-ownership rights.

article thumbnail

IO Biotech raises $155m to develop breakthrough cancer vaccine

pharmaphorum

The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.